Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aripiprazole + chlorpromazine + haloperidol + olanzapine + quetiapine + risperidone
- Development stage
- Unknown
- Lead developer
- Otsuka Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Rectal
01
Overview
This is a combination of six different antipsychotic medications, each with distinct mechanisms of action and side effect profiles. Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 receptors. Chlorpromazine is a first-generation (typical) antipsychotic. Haloperidol is a high-potency first-generation antipsychotic with strong D2 receptor antagonism. Olanzapine is a second-generation (atypical) antipsychotic. Quetiapine is an atypical antipsychotic. Risperidone is an atypical antipsychotic available in long-acting injectable form. Using all six medications simultaneously would be highly unusual in clinical practice, though combinations of two antipsychotics are sometimes used in treatment-resistant cases.
02
Targets
ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)ADRA1 (Alpha-1 adrenergic receptor family)
Beyond the preview
Go deeper on aripiprazole + chlorpromazine + haloperidol + olanzapine + quetiapine + risperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aripiprazole + chlorpromazine + haloperidol + olanzapine + quetiapine + risperidone.